Every instance of this chart that goes below the 'zero' line has indicated a period of recession. See where the chart is currently…
https://fred.stlouisfed.org/series/T10Y3M/
China acknowledging magnetic field degredation an pole shift.
Suspicious0bsservers Ben Davidson is far from alone in his timeline and analysis, it appears.
"Nothing can stop what is coming."-Q
https://www.nejm.org/doi/full/10.1056/NEJMoa1910993
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Abstract
BACKGROUND
Although several experimental therapeutics for Ebola virus disease (EVD) have been developed, the safety and efficacy of the most promising therapies need to be assessed in the context of a randomized, controlled trial.
METHODS
We conducted a trial of four investigational therapies for EVD in the Democratic Republic of Congo, where an outbreak began in August 2018. Patients of any age who had a positive result for Ebola virus RNA on reverse-transcriptase–polymerase-chain-reaction assay were enrolled. All patients received standard care and were randomly assigned in a 1:1:1:1 ratio to intravenous administration of the triple monoclonal antibody ZMapp (the control group), the antiviral agent remdesivir, the single monoclonal antibody MAb114, or the triple monoclonal antibody REGN-EB3. The REGN-EB3 group was added in a later version of the protocol, so data from these patients were compared with those of patients in the ZMapp group who were enrolled at or after the time the REGN-EB3 group was added (the ZMapp subgroup). The primary end point was death at 28 days.
RESULTS
A total of 681 patients were enrolled from November 20, 2018, to August 9, 2019, at which time the data and safety monitoring board recommended that patients be assigned only to the MAb114 and REGN-EB3 groups for the remainder of the trial; the recommendation was based on the results of an interim analysis that showed superiority of these groups to ZMapp and remdesivir with respect to mortality. At 28 days, death had occurred in 61 of 174 patients (35.1%) in the MAb114 group, as compared with 84 of 169 (49.7%) in the ZMapp group (P=0.007), and in 52 of 155 (33.5%) in the REGN-EB3 group, as compared with 79 of 154 (51.3%) in the ZMapp subgroup (P=0.002). A shorter duration of symptoms before admission and lower baseline values for viral load and for serum creatinine and aminotransferase levels each correlated with improved survival. Four serious adverse events were judged to be potentially related to the trial drugs.
CONCLUSIONS
Both MAb114 and REGN-EB3 were superior to ZMapp in reducing mortality from EVD. Scientifically and ethically sound clinical research can be conducted during disease outbreaks and can help inform the outbreak response. (Funded by the National Institute of Allergy and Infectious Diseases and others; PALM ClinicalTrials.gov number, NCT03719586. opens in new tab.)
"Among patients who reported that they had been vaccinated, 38.7% reported that they had received the vaccination at least 10 days before enrollment.
The mean baseline serum creatinine level was 2.5±2.9 mg per deciliter (221±256 μmol per liter), the mean aspartate aminotransferase level was 668±700 U per liter, and the mean alanine aminotransferase level was 379±464 U per liter. The mean baseline creatinine and aspartate aminotransferase values were higher in the ZMapp and remdesivir groups than in the other two groups. However, the baseline creatinine level was not recorded in 18.6% of patients, aspartate aminotransferase level was not recorded in 40.6%, and alanine aminotransferase level was not recorded in 18.1%. In addition, 70.1% of the available baseline samples indicated some degree of hemolysis."
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics, including Remdesivir under NIAID/NIH & Fauci
https://twitter.com/VigilantFox/status/1650126479227863043
The Vigilant Fox 🦊
@VigilantFox
.
@==RobertKennedyJr
"Tony Fauci Knew That Remdesivir Would Kill You"==
"How does it kill you?" he asked. "Kidney failure, heart failure, and all-organ collapse."
"All the doctors said. You heard it again and again. 'We've never seen a virus that attacks the kidneys.' Because it wasn't the virus; it was the remdesivir."
"Tony Fauci Knew That Remdesivir Would Kill You"
baker, pls change notable title for >>19222814 to
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics, incl. Remdesivir under Fauci, NIAID/NIH
ty
o7
fyah